Oryzon Genomics S.A. (0RDB.L)
EUR 3.14
(10.78%)
EUR 3.14
(10.78%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.7 Million USD | 18.3% |
| 2022 | -4.53 Million USD | 15.07% |
| 2021 | -5.33 Million USD | -28.45% |
| 2020 | -4.15 Million USD | -0.47% |
| 2019 | -4.13 Million USD | -206.53% |
| 2018 | -1.34 Million USD | 78.37% |
| 2017 | -6.23 Million USD | -8.74% |
| 2016 | -5.73 Million USD | -432.31% |
| 2015 | -1.07 Million USD | -113.38% |
| 2014 | 8.04 Million USD | 370.79% |
| 2013 | -2.97 Million USD | -388.7% |
| 2012 | -608.29 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 124.48 Thousand USD | 110.05% |
| 2024 Q1 | -1.23 Million USD | 34.89% |
| 2023 Q2 | 1.15 Million USD | 164.96% |
| 2023 FY | -3.7 Million USD | 18.23% |
| 2023 Q1 | -1.77 Million USD | 33.01% |
| 2023 Q4 | -1.9 Million USD | -69.01% |
| 2023 Q3 | -1.12 Million USD | -197.81% |
| 2022 Q2 | 455.68 Thousand USD | 125.15% |
| 2022 Q1 | -1.81 Million USD | 21.8% |
| 2022 FY | -4.53 Million USD | 15.07% |
| 2022 Q4 | -2.64 Million USD | -328.04% |
| 2022 Q3 | -618 Thousand USD | -235.62% |
| 2021 Q3 | -1.83 Million USD | -298.33% |
| 2021 Q2 | 925.74 Thousand USD | 143.4% |
| 2021 FY | -5.33 Million USD | -28.45% |
| 2021 Q4 | -2.31 Million USD | -26.21% |
| 2021 Q1 | -2.13 Million USD | -54.02% |
| 2020 Q1 | -1.15 Million USD | -8.61% |
| 2020 FY | -4.15 Million USD | -0.47% |
| 2020 Q4 | -1.38 Million USD | -51.61% |
| 2020 Q3 | -913.43 Thousand USD | -360.02% |
| 2020 Q2 | -198.56 Thousand USD | 82.79% |
| 2019 FY | -4.13 Million USD | -206.53% |
| 2019 Q4 | -1.06 Million USD | -8.17% |
| 2019 Q2 | -623.55 Thousand USD | 48.34% |
| 2019 Q1 | -1.2 Million USD | -39.69% |
| 2019 Q3 | -982.17 Thousand USD | -57.51% |
| 2018 Q3 | -980.24 Thousand USD | -153.07% |
| 2018 Q4 | -864.13 Thousand USD | 11.85% |
| 2018 FY | -1.34 Million USD | 78.37% |
| 2018 Q2 | 1.84 Million USD | 280.33% |
| 2018 Q1 | -1.02 Million USD | 34.42% |
| 2017 Q2 | -1.64 Million USD | -27.73% |
| 2017 Q1 | -1.28 Million USD | 5.34% |
| 2017 Q4 | -1.56 Million USD | -33.96% |
| 2017 Q3 | -1.16 Million USD | 29.16% |
| 2017 FY | -6.23 Million USD | -8.74% |
| 2016 Q3 | -1.35 Million USD | 40.98% |
| 2016 FY | -5.73 Million USD | -432.31% |
| 2016 Q4 | -1.36 Million USD | -0.21% |
| 2016 Q2 | -2.3 Million USD | -217.84% |
| 2016 Q1 | -724.15 Thousand USD | -5.59% |
| 2015 Q4 | -685.82 Thousand USD | -78.3% |
| 2015 Q1 | -738.09 Thousand USD | -76.91% |
| 2015 Q2 | 849.14 Thousand USD | 215.04% |
| 2015 FY | -1.07 Million USD | -113.38% |
| 2015 Q3 | -384.64 Thousand USD | -145.3% |
| 2014 Q4 | -417.2 Thousand USD | 4.09% |
| 2014 Q2 | 3.66 Million USD | -0.0% |
| 2014 Q3 | -435 Thousand USD | -111.85% |
| 2014 FY | 8.04 Million USD | 370.79% |
| 2014 Q1 | 3.66 Million USD | 0.0% |
| 2013 FY | -2.97 Million USD | -388.7% |
| 2012 FY | -608.29 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Boiron SA | 35.82 Million EUR | 110.332% |
| Laboratorios Farmaceuticos Rovi, S.A. | 170.33 Million EUR | 102.173% |
| Vetoquinol SA | 55.56 Million EUR | 106.662% |
| Valneva SE | -101.42 Million EUR | 96.351% |
| AB Science S.A. | -10.04 Million EUR | 63.16% |
| Nanobiotix S.A. | -39.7 Million EUR | 90.676% |
| PHAXIAM Therapeutics S.A. | -23.48 Million EUR | 84.24% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 86.939% |
| BioSenic S.A. | -28.77 Million EUR | 87.137% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 97.494% |
| Formycon AG | 75.79 Million EUR | 104.884% |